Silence Therapeutics (SLN) Current Assets (2018 - 2026)

Silence Therapeutics has reported Current Assets for 9 years, with the latest figure at $102.9 million in Q1 2026.

• Quarterly Current Assets fell 39.42% year-over-year to $102.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.9 million (down 39.42% YoY) and the FY2025 annual result came in at $118.7 million, down 36.67% from the prior year.
• Current Assets fell to $102.9 million in Q1 2026 per SLN's latest filing, from $118.7 million in the prior quarter.
• Over five years, Current Assets peaked at $187.4 million in Q4 2024 and troughed at $100.6 million in Q4 2023.
• A 5-year average of $134.4 million and a median of $126.1 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2026: Current Assets jumped 86.32% in 2024, then slumped 39.42% in 2026.
• Over 5 years, Current Assets stood at $113.4 million in 2022, then fell by 11.33% to $100.6 million in 2023, then surged by 86.32% to $187.4 million in 2024, then slumped by 36.67% to $118.7 million in 2025, then dropped by 13.32% to $102.9 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $102.9 million, $118.7 million, and $133.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.